# NeoGenomics, Inc. (NEO)

> Source: Nexqual · https://nexqual.com/NEO · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, NeoGenomics, Inc. (NEO), nexqual.com/NEO" · informational, not investment advice.

**Price:** USD 17.25 (+2.19% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 16.88 · day 16.61–17.34 · 52w 7.07–20.15 · market cap $2.22B · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $766M, net income -$51.9M (-6.8% margin), free cash flow -$7.4M (SEC filings).
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 21.85 (range 16.5–35).
- Total return with dividends: 1Y +67.8% vs S&P 500 +18.1%; 5Y -60.2% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD 0.06, revenue estimate $207M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $484M | $510M | $592M | $661M | $727M | $766M |
| Gross profit | $187M | $188M | $245M | $290M | $314M | — |
| Operating income | -$119M | -$158M | -$108M | -$92.1M | -$116M | -$68.4M |
| Net income | -$8.3M | -$144M | -$88.0M | -$78.7M | -$108M | -$51.9M |
| Free cash flow | -$90.9M | -$96.9M | -$30.7M | -$34.0M | -$21.8M | -$7.4M |
| Gross margin | 38.6% | 36.9% | 41.3% | 43.9% | 43.2% | — |
| Operating margin | -24.5% | -30.9% | -18.2% | -13.9% | -15.9% | -8.9% |
| Net margin | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% | -6.8% |
| Revenue growth | +9.0% | +5.2% | +16.1% | +11.6% | +10.1% | — |
| Cash + short-term investments | $515M | — | — | $367M | $160M | — |
| Total debt | $533M | $535M | $538M | $541M | $342M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.9x · EV/Sales 3.2x · P/B 2.8x · FCF yield -0.33% · Earnings yield -2.34% · Net debt $229M · EV $2.44B

## Analysts
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 21.85 (low 16.5, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | StoneX | Target raised | Buy | $16 → $20 |
| 2026-10-06 | Needham | Target raised | Buy | $19 → $22 |
| 2026-10-06 | BTIG | Upgrade | Neutral → Buy | $28 |
| 2026-07-29 | Needham | Target raised | Buy | $15 → $19 |
| 2026-07-24 | Benchmark | Target raised | Buy | $11 → $16 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +67.8% | -60.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +68.1% | -16.8% |
| Volatility (annualized) | 53.5% | 67.5% |
| Max drawdown | -45.6% (Jan 2026→Mar 2026) | -88.8% (Oct 2021→Jul 2025) |

## Peers (Diagnostics & Research)
WGS (GeneDx Holdings Corp.) USD 70.22 +8.10% · PSNL (Personalis, Inc.) USD 15.93 +0.50% · CDNA (CareDx, Inc.) USD 66.68 +1.90% · VCYT (Veracyte, Inc.) USD 44.39 +2.97% · FRNM (Freenome, Inc.) USD 12.29 -2.81% · ADPT (Adaptive Biotechnologies Corpor) USD 25.58 +1.19%

## More
Full page: https://nexqual.com/NEO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt